Cure My Disease

Don't miss your cure!

 Log in / Sign up

What doctors really choose for polycythemia vera: a french record review

NCT ID NCT07839858

Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 24, 2026 · Last updated Sep 25, 2026 · Updated 1 time

Summary

Researchers are reviewing medical records from 237 patients in France with polycythemia vera, a blood disorder where the body makes too many red blood cells. The study focuses on patients who started a second-line cytoreductive treatment between 2022 and 2023. It aims to describe which treatments doctors choose, why they switch, how well the treatments work in real life, and what side effects occur.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
The findings could help doctors understand which second-line treatments for polycythemia vera work best in everyday practice and why they switch therapies.
What could go wrong
This is a retrospective review of past medical records, so it can only show patterns and associations, not prove cause and effect. The results may not apply to other countries or newer treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

237 people

The number who actually took part.

Started

Mar 2025

Finished

Oct 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with PV who received a first dose of a second-line cytoreductive treatment between 1 January 2022 and 31 December 2023.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: 1. Male or female patient diagnosed with PV after 01 Jan 2014 according to World Health Organization (WHO) criteria. 2. Patient ≥ 18 years of age at the time of PV diagnosis. 3. Patient who received a first dose of a second-line cytoreductive treatment between 01 Jan 2022 and 31 Dec 2023. Exclusion criteria: 1. Patient alive at study initiation who opposed to data use for research purposes. 2. Patient who died before study initiation and who had opposed to data use for research purpose prior to their death. 3. Patient who took part in an interventional clinical trial(s) between 01 January 2022 and 31 December 2023.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Polycythemia vera are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired polycythemia vera

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Polycythemia vera

Contacts and locations

Locations

  • Novartis Investigative Site

    Bayonne, Bayonne Cedex, 64109, France

  • Novartis Investigative Site

    Saint Priest Jarez, Pays de la Loire Region, 42270, France

  • Novartis Investigative Site

    Aix-en-Provence, 13616, France

  • Novartis Investigative Site

    Amiens, 80054, France

  • Novartis Investigative Site

    Angers, 49933, France

  • Novartis Investigative Site

    Antony, 92160, France

  • Novartis Investigative Site

    Arras, 62022, France

  • Novartis Investigative Site

    Aurillac, 15000, France

  • Novartis Investigative Site

    Avignon, 84000, France

  • Novartis Investigative Site

    Béziers, 34525, France

  • Novartis Investigative Site

    Bordeaux, 33076, France

  • Novartis Investigative Site

    Brest, 29200, France

  • Novartis Investigative Site

    Cesson-Sévigné, 35576, France

  • Novartis Investigative Site

    Challes-les-Eaux, 73190, France

  • Novartis Investigative Site

    Chambéry, 73000, France

  • Novartis Investigative Site

    Clermont-Ferrand, 63003, France

  • Novartis Investigative Site

    Corbeil-Essonnes, 91100, France

  • Novartis Investigative Site

    Dunkirk, 59240, France

  • Novartis Investigative Site

    Essey-lès-Nancy, 54270, France

  • Novartis Investigative Site

    Grenoble, 38043, France

  • Novartis Investigative Site

    Le Bouscat, 33110, France

  • Novartis Investigative Site

    Le Chesnay, 78150, France

  • Novartis Investigative Site

    Le Coudray, 28630, France

  • Novartis Investigative Site

    Le Kremlin-Bicêtre, 94275, France

  • Novartis Investigative Site

    Le Mans, 72000, France

  • Novartis Investigative Site

    Libourne, 33505, France

  • Novartis Investigative Site

    Lille, 59037, France

  • Novartis Investigative Site

    Lyon, 69373, France

  • Novartis Investigative Site

    Marseille, 13005, France

  • Novartis Investigative Site

    Montpellier, 34295, France

  • Novartis Investigative Site

    Morlaix Cdex, 29672, France

  • Novartis Investigative Site

    Nantes, 44277, France

  • Novartis Investigative Site

    Nîmes, 30029, France

  • Novartis Investigative Site

    Orléans, 45100, France

  • Novartis Investigative Site

    Paris, 75013, France

  • Novartis Investigative Site

    Paris, 75014, France

  • Novartis Investigative Site

    Paris, 75015, France

  • Novartis Investigative Site

    Paris, 75475, France

  • Novartis Investigative Site

    Perpignan, 66046, France

  • Novartis Investigative Site

    Pessac, 33604, France

  • Novartis Investigative Site

    Pierre-Bénite, 69310, France

  • Novartis Investigative Site

    Poitiers, 86021, France

  • Novartis Investigative Site

    Quimper, 29000, France

  • Novartis Investigative Site

    Rennescedex9, 35033, France

  • Novartis Investigative Site

    Rochefort, 17301, France

  • Novartis Investigative Site

    Roubaix, 59100, France

  • Novartis Investigative Site

    Saint-Brieuc, 22000, France

  • Novartis Investigative Site

    St-Malo, 35400, France

  • Novartis Investigative Site

    Strasbourg, 67085, France

  • Novartis Investigative Site

    Trévenans, 90400, France

  • Novartis Investigative Site

    Troyes, 10003, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.